Free Trial
LON:GNS

Genus (GNS) Share Price, News & Analysis

Genus logo
GBX 1,644 -42.00 (-2.49%)
(As of 11:52 AM ET)

About Genus Stock (LON:GNS)

Key Stats

Today's Range
1,644
1,714
50-Day Range
1,686
2,153.40
52-Week Range
1,478
2,378
Volume
67,223 shs
Average Volume
119,203 shs
Market Capitalization
£1.08 billion
P/E Ratio
13,700.00
Dividend Yield
1.95%
Price Target
GBX 2,150
Consensus Rating
Buy

Company Overview

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.

Genus Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
43rd Percentile Overall Score

GNS MarketRank™: 

Genus scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Genus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Genus has received no research coverage in the past 90 days.

  • Read more about Genus' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Genus is 13,750.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 125.73.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Genus is 13,750.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 91.28.

  • Price to Earnings Growth Ratio

    Genus has a PEG Ratio of 2.87. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Genus has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for GNS.
  • Dividend Yield

    Genus pays a meaningful dividend of 1.56%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Genus does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Genus is 26,666.67%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Read more about Genus' dividend.
  • Short Interest

    There is no current short interest data available for GNS.
  • Search Interest

    8 people have searched for GNS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Genus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Genus insiders have bought 26.29% more of their company's stock than they have sold. Specifically, they have bought £54,000 in company stock and sold £42,758.16 in company stock.

  • Percentage Held by Insiders

    Only 0.75% of the stock of Genus is held by insiders.

  • Percentage Held by Institutions

    77.79% of the stock of Genus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Genus' insider trading history.
Receive GNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genus and its competitors with MarketBeat's FREE daily newsletter.

GNS Stock News Headlines

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217
High Growth Tech Stocks In The United Kingdom
Exploring High Growth Tech Stocks In The United Kingdom
See More Headlines

GNS Stock Analysis - Frequently Asked Questions

Genus' stock was trading at GBX 2,170 at the start of the year. Since then, GNS shares have decreased by 24.0% and is now trading at GBX 1,650.
View the best growth stocks for 2024 here
.

Shares of GNS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genus investors own include Meta Platforms (META), Lloyds Banking Group (LLOY), Rolls-Royce Holdings plc (RR.L), AstraZeneca (AZN), Barclays (BARC), BP (BP) and Clinigen Group (CLIN).

Company Calendar

Ex-Dividend for 12/6 Dividend
11/07/2024
Today
11/21/2024
Dividend Payable
12/06/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Personal Services
CIK
N/A
Fax
N/A
Employees
480
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 2,150
High Stock Price Target
GBX 2,150
Low Stock Price Target
GBX 2,150
Potential Upside/Downside
+30.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
£7.90 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£668.80 million
Cash Flow
GBX 32.63 per share
Book Value
GBX 835 per share

Miscellaneous

Free Float
N/A
Market Cap
£1.08 billion
Optionable
Not Optionable
Beta
0.37
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (LON:GNS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners